CN105362296A - Lactic acid bacteria nasal wash - Google Patents
Lactic acid bacteria nasal wash Download PDFInfo
- Publication number
- CN105362296A CN105362296A CN201510839472.0A CN201510839472A CN105362296A CN 105362296 A CN105362296 A CN 105362296A CN 201510839472 A CN201510839472 A CN 201510839472A CN 105362296 A CN105362296 A CN 105362296A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- nasal
- wash
- nasal cavity
- nasal wash
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates a lactic acid bacteria nasal wash comprising a diluent and at least one lactic acid bacterium. The total content of the lactic acid bacteria is not less than 100 cfu/ml. The nasal wash can be used to wash the nose, clearing nasal cavity dirt and improving the relative ratio of lactic acid bacteria in the nasal cavity, thereby increasing the ratio of beneficial bacteria in upper and lower respiratory tracts. The nasal wash can be used to wash the nose, improving original bacterial imbalance in the nasal cavity, reconstructing normal flora in respiratory tracts and reducing respiratory inflammations and allergies. Meanwhile, in continuous ciliary movement, the nasal wash also helps supplement high-activity probiotics for gastrointestinal tracts through the respiratory tract mucous blanket. The nasal wash is a new means to improve flora in the respiratory system and digestive system and is well functional in preventing and treating upper and lower respiratory tract diseases caused by microorganisms. New uses and a new applicable field are developed for lactic acid bacteria.
Description
Technical field
The present invention relates to a kind of mixture of nasal cavity cleaning, the lactobacillus nasal wash of nasal cavity lactobacillus relative scale after especially a kind of cleaning, can be improved.
Background technology
Nasal cavity cleaning is a kind of cleaning-nursing means of upper respiratory tract.Concrete grammar is mainly: pour into nostril with liquid, and itself and nasal cavity surface are fully contacted, and washes away after nasal cavity mucus and dirt from oral cavity or nostril outflow.Nasal cavity cleaning can remove air pollution and accumulate in dirt in nasal cavity, microorganism.Also for the routine cleaning of postoperative nasal endoscopic incrustation decortication.Because nasal cavity cleaning is to the remarkable effect of rhinitis and sinusitis, nasal cavity cleaning is widely used in medical treatment and daily nasal cavity and washes and protect.In order to fully to contact the liquid on nasal cavity surface during nasal cavity cleaning, be referred to as nasal wash.
In order to alleviate or prevent the edema of nasal mucosa, general nasal wash can not use fresh water, and can use the osmotic pressure of the sodium chloride adjustment nasal wash of 0.5-6%.Conventional nasal wash has normal saline, strong brine, and ringer's solution.The cleaning of these traditional nasal wash, the antibacterial mucus of nasal cavity, foreign body can driven away indistinction and be attached on above-mentioned object.Obviously, the relative scale of lactobacillus and other antibacterials in nasal cavity can not be significantly improved after this indifference cleaning.
Some nasal wash can add at least one broad-spectrum antibacterial medicine (as gentamycin) in addition, also can kill the antibacterial of nasal cavity while removing foreign body.No matter above-mentioned broad-spectrum antibacterial medicine is to lactobacillus, or the suppression of other microorganisms to kill be all indiscriminate.After this antibacterial type nasal wash nasal cavity cleaning, while reducing pathogenic bacterium, also significantly can reduce the lactobacillus of nasal cavity.Obviously, existing antibacterial type nasal wash, also can not significantly improve the relative scale of lactobacillus and other antibacterials in cleaning posterula.
Up-to-date research shows, the antibacterial in nasal cavity is not " be all harmful to " as traditional view is thought.In fact, the existence of some lactobacilluss in the Respiratory tract microbial population of normal person, can suppress the excessive multiplication of harmful bacteria, and participates in the immunne response of adjustment nasal mucosa.There is beneficial effect to human body in these lactobacilluss, is also referred to as probiotic bacteria.Therefore, the ratio improving lactobacillus (especially specific lactobacillus) in cleaning posterula is more useful to the nursing of upper respiratory tract.But no matter whether have broad-spectrum sterilization function, existing nasal wash all deposits the deficiency that can not improve nasal cavity lactobacillus relative scale after cleaning.
Summary of the invention
In order to the deficiency of lactobacillus relative scale in nasal cavity can not be improved after overcoming existing nasal wash nasal cavity cleaning, the invention provides a kind of lactobacillus nasal wash, this lactobacillus nasal wash can not only the dirt of nasal cavity cleaning, and can improve lactobacillus relative scale in cleaning posterula, suppresses pathogenic bacterium.
The technical solution adopted for the present invention to solve the technical problems is: a kind of lactobacillus nasal wash, is characterized in that: comprise diluent and at least one lactobacillus, and lactobacillus total content is not less than 100cfu/ml.
Preferably, lactobacillus nasal wash should comprise sodium chloride, and content is 0.5-5%.
Further preferably, should at least comprise a kind of lactobacillus in lactobacillus nasal wash, and lactobacillus content is not less than 100cfu/ml.
Traditional idea is thought " only have nasal cavity front portion just to have antibacterial, do not have antibacterial at nasal cavity rear portion ".Traditional idea is also thought " antibacterial is all be unfavorable for nasal cavity hygienic and health ".But in fact, all there is antibacterial in the whole respiratory tract of normal person.Being not only nasal cavity front portion, also there is a large amount of antibacterial in the mucosa at nasal cavity rear portion.After the detection method of nasal cavity antibacterial is improved, be no matter the upper respiratory tract at healthy human body, or all find hundreds of Resident bacteria at the lower respiratory tract of healthy human body.And the bacterial species of lower respiratory tract enriches degree identical with upper respiratory tract (the quantity relative rarity of just often kind of microorganism).
As the organ having bacterium air constantly to pass through, in nasal cavity, the existence of a large amount of antibacterial is originally inevitable.The flora of nasal cavity comprises useful antibacterial (probiotic bacteria), conditioned pathogen, and harmful pathogenic bacterium.Antibacterial useful in nasal cavity mainly lactobacillus.Lactobacillus on nasal mucosa can pass through the means such as antagonism, occupy-place, secretion antibiotics and suppress harmful bacteria, prevents pathogenic bacterium in the excessive growth of nasal cavity.Part lactobacillus (as Lactobacillus salivarius, bacillus acidophilus etc.) can also with nasal mucosa reciprocal action, form rational mucosal immune response, thus the various disease that causes of harmful microorganism such as control virus, antibacterial, fungus etc. and allergy.In the normal flora of nasal cavity, the existence of lactobacillus higher level is the important basis of respiratory tract one of keeping fit.
The structure of nasal cavity is complicated, and the distribution of antibacterial neither be uniform.In the easier field planting of some position microorganisms of nasal mucosa, and other position microorganic adhesion is very difficult.Exactly because on nasal cavity inwall specific region, the reduction of lactic acid bacterium number and even exhaustion, the exception that result in pathogenic bacterium or conditioned pathogen in nasal cavity increases, thus creates a series of disease such as rhinitis, sinusitis.
Interact with nasal mucosa, maintain the lactobacillus of nasal cavity flora ecology, comprise Lactobacillus salivarius and Lactobacillus saki.By supplementing Lactobacillus salivarius and/or Lactobacillus saki to nasal cavity, can produce and improve nasal cavity flora environment, suppress pathogenic bacterium, reduce obvious effect of nasal cavity inflammation.
Technical scheme of the present invention and traditional thinking, " supplement lactobacillus to gastrointestinal tract and alleviate allergic rhinitis " is totally different, and such with " nasal cavity should be aseptic " the especially conventional sanitation idea of technical concept of the present invention is completely contrary.The present invention by adding lactobacillus (especially comprising Lactobacillus salivarius, this kind of lactobacillus having biological effect of Lactobacillus saki) in diluent, and make in the cleaning process of nasal cavity, high-caliber lactobacillus fully contacts constantly with the whole inner surface of nasal cavity.Above-mentioned contact be comprehensively wash away attachment, large area covers residual.Relative to a small amount of contact of nasal cavity drip, aforesaid way has larger probability to complete the attachment of lactobacillus at the nasal cavity position being easy to field planting.This lactobacillus liquid that contains is to comprehensive cleaning of nasal cavity, under the prerequisite reducing nasal cavity dirt and total number of bacteria, add separately the residual amount of lactobacillus, thus improve the relative scale of its inner surface lactobacillus after reaching nasal cavity cleaning, suppress the object of pathogenic bacterium.
Another important technology object of the present invention is also, provides a kind of Lactobacillus and more efficiently takes in gastrointestinal indirect channel.
After using the present invention's cleaning, the lactobacillus increased in nasal cavity constantly can enter esophagus with mucous blanket by ciliary movement.Owing to not having food stimulus, gastrointestinal tract can not secrete a large amount of highly active Digestive system at this moment.The lactobacillus of ciliary movement conveying enters gastrointestinal tract and the feed of various condition and unconditional can't be caused to react.Lactobacillus in mucus blanket, will face killing and wounding of less (and activity lower Digestive system).Therefore, by nasal cavity cleaning, the gastral lactobacillus that is ingested after nasal cavity increment just can have larger probability by keeping activity during gastrointestinal tract, also completely more for a long time can rest on gastrointestinal tract, and easier field planting is on gastrointestinal tract mucous.Relative to food, the oral lactobacillus of beverage, tablet, application the present invention takes in lactobacillus and more easily will play its biological effect.Above-mentioned biological effect just comprises and alleviates various anaphylactic disease, especially allergic rhinitis.
The present invention develops the new purposes of a class to lactobacillus, has opened up a new application.The invention has the beneficial effects as follows, while removing nasal cavity dirt, improve lactobacillus relative scale in nasal cavity, and then improve the probiotics level of upper respiratory tract and lower respiratory tract.By antagonism, the competition of more lactobacilluss, recovery and the growth of pathogenic bacterium in nasal cavity can be suppressed.Leave more lactobacilluss after using nasal cavity cleaning of the present invention, it is unbalance to improve original antibacterial, prevents the lactobacillus exhaustion of nasal cavity, rebuilds respiratory tract normal flora, reduces respiratory inflammation and allergic phenomena.The present invention with respiratory tract mucus blanket, can also supplement high-activity lactic acid bacteria to gastrointestinal tract in the ciliary movement continued.Taken in the process of lactobacillus by the present invention, greatly reduce Digestive system killing and wounding lactobacillus, can more effectively improve gastrointestinal flora than oral lactobacillus.The present invention is the brand-new means improving whole respiratory system flora and adjustment digestive system flora, and the upper and lower respiratory tract disease caused for microorganism all has good preventive and therapeutic effect.
Detailed description of the invention
All features disclosed in this description, or disclosed all methods, or the step in process, all can be combined in any way except mutually exclusive feature and/or step.
In embodiment one, lactobacillus nasal wash comprises diluent and at least one lactobacillus, and lactobacillus total content is not less than 100cfu/ml.Lactobacillus used at least comprises Lactobacillus salivarius, is preferably and all uses the freezing mycopowder of saliva lactobacillus.Diluent then adopts aseptic warm water.By the Lactobacillus salivarius lyophilizing mycopowder of 0.1 gram 10,000,000,000 cfu/ gram, drop in the aseptic warm water of 100ml and be prepared as nasal wash.Above-mentioned aseptic warm water is preferably the distilled water of 30-40 degree Celsius.After above-mentioned lyophilizing mycopowder is evenly mixed in distilled water, the content of lactic acid bacteria of gained nasal wash is that 1,000 ten thousand cfu/ml(are greater than 100cfu/ml).
The above-mentioned lactobacillus nasal wash of preparation is loaded nasal-cavity cleaner, after during nasal cavity cleaning, while removal nasal cavity dirt, can significantly increase the relative populations of nasal cavity lactobacillus (Lactobacillus salivarius).
In embodiment two, lactobacillus nasal wash at least comprises a kind of lactobacillus, and lactobacillus content is not less than 100cfu/ml.The combination of the preferred Lactobacillus salivarius of the present embodiment lactobacillus used and Lactobacillus saki.Lactobacillus salivarius adopts the Lactobacillus salivarius lyophilizing mycopowder of 0.1 gram of content 10,000,000,000 cfu/ gram.Lactobacillus saki adopts the Lactobacillus saki lyophilizing mycopowder of 0.02 gram of content 10,000,000,000 cfu/ gram.Diluent is the aseptic warm water of 99ml.The present embodiment also comprises sodium chloride, and content is 0.5-5%.Be preferably 0.9%.
Above-mentioned two kinds of lyophilizing mycopowder and sodium chloride are thrown in the aseptic warm water of 99ml, stirs.The lactobacillus nasal wash saliferous 0.9% obtained, lactobacillus total content is 1,200 ten thousand cfu/ml.Above-mentioned nasal wash is loaded in undine, cleans respectively from two nostrils.Isotonic saline solution contributes to comfort during nasal cavity cleaning, is also conducive to cleaning rear probiotic bacteria in the attachment of nasal mucosa and increment.
In embodiment three, lactobacillus nasal wash comprises the antibacterial substance that at least one antimicrobial spectrum does not cover lactobacillus.The antibacterial substance that antimicrobial spectrum does not cover lactobacillus comprises sodium diacetate, dehydro sodium acetate, pimaricin, amphotericin B etc.The preferred sodium diacetate of the present embodiment and pimaricin composite.0.1 milligram of sodium diacetate, with 0.05 milligram of pimaricin, with the Lactobacillus saki lyophilizing mycopowder of 0.1 gram of content 10,000,000,000 cfu/ gram, and Lactobacillus acidophilus's lyophilizing mycopowder of 0.02 gram of content 10,000,000,000 cfu/ gram, 0.9 gram of sodium chloride, jointly throws in the aseptic warm water of 99ml, stirs.The lactobacillus nasal wash obtained, has Antifungi but the character of less lactic acid bacteria inhibiting.Load with the nasal wash of the present embodiment and wash nose device lavation nasal cavity, or to spray profit nasal cavity in loading spray bottle, the relative populations of lactobacillus in nasal cavity (relative populations especially between lactobacillus and fungus) can be increased.Contrary with lactobacillus, fungus is obviously harmful to nasal cavity health, is the pathogenic bacterium causing nasal cavity pathological changes.
In embodiment four, antibacterial substance, lactobacillus, diluent, sodium chloride all adopts identical proportioning with embodiment three, but adding gel is made into gel nasal wash.Gel selects arabic gum.Gelatinous lactobacillus nasal wash is spread upon in nasal cavity.After nasal wash flows out with nasal secretion, lactobacillus and selectivity antibacterial substance can play a role.The relative populations of the nasal cavity lactobacillus after cleaning can increase considerably.
In embodiment five, lactobacillus nasal wash comprises the impregnation liquid of at least one plant.Be preferably Flos Magnoliae impregnation liquid.20 grams of Flos Magnoliae are added 0.9 gram of sodium chloride.Flood and obtain Flos Magnoliae impregnation liquid in 8 days, add 80 grams of warm water, and 0.1 gram of content is the Lactobacillus salivarius lyophilizing mycopowder of 10,000,000,000 cfu/ grams, and the Lactobacillus salivarius lyophilizing mycopowder of 0.01 gram of content 1,000 hundred million cfu/ gram.Get supernatant after abundant stirring, the lactobacillus nasal wash containing planting dip composition can be obtained.This lactobacillus nasal wash, except increasing the rear lactobacillus relative populations of cleaning, also can form the therapeutic efficiency of active components of plants.Above-mentioned nasal wash loading is washed lavation in nose device and can be obtained good experience.
In embodiment six, lactobacillus nasal wash comprises squeezing the juice of at least one plant.The present embodiment is preferably lotus root juice.Add 20 grams of warm water after being squeezed the juice by 89 grams of Rhizoma Nelumbiniss, then add 0.9 gram of sodium chloride, the Lactobacillus salivarius lyophilizing mycopowder of 0.1 gram of content 10,000,000,000 cfu/ gram, 0.1 milligram of sodium diacetate, stirs after mixing.The lactobacillus nasal wash obtained adds washes nose device nasal cavity cleaning.Lotus root juice can be supplied to the nutrition of Lactobacillus plantarum breeding, also has the active components of plants promoting rhinitis recovery from illness.
In embodiment seven, lactobacillus nasal wash comprises at least one plant extract.The preferred Fructus Xanthii extract of the present embodiment.By 3 grams of Fructus Xanthii extracts, 0.9 gram of sodium chloride, the Lactobacillus salivarius lyophilizing mycopowder of 0.1 gram 10,000,000,000 cfu/ gram.Be sealed in plastic bag after mixing.Cryopreservation, through when needing to use, open above-mentioned plastic bag, drop in 97 grams of distilled water.Sealing and standing puts 1-3 days.Get clear liquor and namely obtain highly active lactobacillus nasal wash.Fructus Xanthii extract wherein, containing strumaroside, xanthanol, isoxanthanol, xanthumin isoreactivity material, has the biological effect of clearing the nasal passage.
In embodiment eight, lactobacillus nasal wash comprises acidity regulator.Acidity regulator can change the target acid basicity of nasal wash, realizes with applicable cleaning object.Acidity regulator comprises sodium bicarbonate, citric acid, lactic acid ... the preferred anhydrous citric acid of acidity regulator of the present embodiment.Above-mentioned acidity regulator can make lactobacillus nasal wash in acid, to facilitate lactobacillus in the growth of nasal cavity.
1 gram of citric acid, the Lactobacillus salivarius lyophilizing mycopowder of 0.1 gram 10,000,000,000 cfu/ gram, 0.9 gram of sodium chloride are packaged in sealing bag.When needing to use, solid mixture is mixed with 98 milliliters of warm waters, shake up rear loading and wash nose device nasal cavity is cleaned.
In embodiment nine, lactobacillus nasal wash at least comprises Lactobacillus saki.And comprise several mineral materials.Lactobacillus nasal wash is by 0.02 gram of calcium chloride, 0.03 gram of potassium chloride, 0.6 gram of sodium chloride, the Lactobacillus saki lyophilizing mycopowder of 0.31 gram of sodium lactate and 0.1 gram 10,000,000,000 cfu/ gram, the bifidobacteria infantis lyophilizing mycopowder of 0.1 gram 10,000,000,000 cfu/ gram, the Lactobacillus salivarius lyophilizing mycopowder of 0.1 gram 10,000,000,000 cfu/ gram, is packaged in sealing bag after mixing.When needing to wash nose, said mixture is taken out from sealing bag, mix with 100 milliliters of warm water, obtain the hartman's solution containing composite lactobacillus.Above-mentioned solution can be used for washing nose at postoperative nasal endoscopic.The dysbacteriosis that while helping cleaning incrustation, conditioning nasal cavity is postoperative.Lactobacillus in nasal wash can in nasal cavity all mucosal sites of comprehensive engagement, and suitable place (as nasal sinuses) increment grow up.Be not attached to the part lactobacillus on nasal mucosa, with ciliary movement, brought into digestive tract by mucous blanket.Above-mentioned Lactobacillus, when entering gastrointestinal tract, can not cause a large amount of secrete digestive juices of gastrointestinal tract, and have mucous blanket to protect, and the longer time can be kept in the gastrointestinal tract active, therefore, and can also the flora of more effectively recuperating gastrointestinal tract after conditioning nasal cavity flora.
In embodiment ten, lactobacillus nasal wash is made up of sodium chloride and lactobacillus and water, and wherein the content of sodium chloride is 0.5-5%, and the content of lactobacillus is 10
2-10
11cfu/ milliliter, and at least comprise Lactobacillus salivarius 100cfu/ml.The content of sodium chloride is preferably 0.9 gram.Lactobacillus is preferably Lactobacillus salivarius, Lactobacillus paracasei, lactococcus lactis subsp.cremoris, Streptomyces thermophilus, bifidobacterium adolescentis, Lactobacillus plantarum, Lactobacillus acidophilus's 7 kinds of lactobacilluss are composite.Choose above-mentioned 7 kinds of lactobacilluss, content is each 0.3 gram of the lyophilizing mycopowder of 10,000,000,000 cfu/ grams, is packaged in sealed plastic bag with 2.7 grams of sodium chloride.Cryopreservation.When needing nasal cavity cleaning, above-mentioned sealing bag is opened, content is mixed homogeneously with 300 ml distilled waters, obtain lactobacillus nasal wash.Above-mentioned nasal wash is loaded in nose sucking device, to nasal cavity cleaning.After can removing nasal cavity dirt, mucus remains, and improves the lactobacillus level of nasal cavity.Lactobacillus unnecessary in nasal cavity, flows into esophagus with mucus blanket after increment, can also improve the lactobacillus level of the intestines and stomach, adjustment gastrointestinal flora.
Claims (10)
1. a lactobacillus nasal wash, is characterized in that: comprise diluent and at least one lactobacillus, and lactobacillus total content is not less than 100cfu/ml.
2. lactobacillus nasal wash according to claim 1, is characterized in that: comprise sodium chloride, and content is 0.5-5%.
3. lactobacillus nasal wash according to claim 2, it is characterized in that: at least comprise a kind of lactobacillus, and lactobacillus content is not less than 100cfu/ml.
4. lactobacillus nasal wash according to claim 3, is characterized in that: at least comprise a strain Lactobacillus salivarius, and Lactobacillus salivarius content is not less than 100cfu/ml.
5. the lactobacillus nasal wash according to claim 2 and any one of claim 3, is characterized in that: the impregnation liquid comprising at least one plant.
6. the lactobacillus nasal wash according to claim 2 and any one of claim 3, is characterized in that: comprise at least one plant extract.
7. the lactobacillus nasal wash according to claim 2 and any one of claim 3, is characterized in that: comprise the antibacterial substance that at least one antimicrobial spectrum does not cover lactobacillus.
8. the lactobacillus nasal wash according to claim 2 and any one of claim 3, is characterized in that: comprise acidity regulator.
9. the lactobacillus nasal wash according to claim 2 and any one of claim 3, is characterized in that: be made up of sodium chloride and lactobacillus and water, wherein the content of sodium chloride is 0.5-5%, and the content of lactobacillus is 10
2-10
11cfu/ milliliter, and at least comprise Lactobacillus salivarius 100cfu/ml.
10. the lactobacillus nasal wash according to claim 2 and any one of claim 3, is characterized in that: at least comprise Lactobacillus saki.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510839472.0A CN105362296A (en) | 2015-11-27 | 2015-11-27 | Lactic acid bacteria nasal wash |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510839472.0A CN105362296A (en) | 2015-11-27 | 2015-11-27 | Lactic acid bacteria nasal wash |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105362296A true CN105362296A (en) | 2016-03-02 |
Family
ID=55365250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510839472.0A Pending CN105362296A (en) | 2015-11-27 | 2015-11-27 | Lactic acid bacteria nasal wash |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105362296A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018188124A1 (en) * | 2017-04-11 | 2018-10-18 | 成都益植生物科技有限公司 | Colonizing probiotic preparation, applications thereof, and medicament |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1357038A (en) * | 1999-06-21 | 2002-07-03 | Vsl制药有限公司 | Combination of lactic acid bacteria and its use for prevention and/or treatment of infections and inflammatory conditions |
| CN1479788A (en) * | 2000-09-25 | 2004-03-03 | �Ʒ� | Lactic acid bacteria capable of reducing indvidual's tendency to develop allergic reactions |
| CN1696281A (en) * | 2004-05-10 | 2005-11-16 | 景岳生物科技股份有限公司 | New microbe gene stock similar to lactobacillus casei GM-O80, and application for treating disease related to irritability |
| CN1913906A (en) * | 2003-12-17 | 2007-02-14 | 纽迪西亚公司 | Lactic acid producing bacteria and lung function |
| CN102008513A (en) * | 2009-09-04 | 2011-04-13 | 蒋盛军 | Method for controlling high swine fever by using nose atomization microecological preparation |
| CN102579687A (en) * | 2012-02-27 | 2012-07-18 | 程相国 | Nasal cavity Chinese medicinal washing fluid |
| CN103502434A (en) * | 2011-05-06 | 2014-01-08 | 有机平衡医疗股份公司 | Novel lactic acid bacteria and compositions containing them |
-
2015
- 2015-11-27 CN CN201510839472.0A patent/CN105362296A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1357038A (en) * | 1999-06-21 | 2002-07-03 | Vsl制药有限公司 | Combination of lactic acid bacteria and its use for prevention and/or treatment of infections and inflammatory conditions |
| CN1479788A (en) * | 2000-09-25 | 2004-03-03 | �Ʒ� | Lactic acid bacteria capable of reducing indvidual's tendency to develop allergic reactions |
| CN1913906A (en) * | 2003-12-17 | 2007-02-14 | 纽迪西亚公司 | Lactic acid producing bacteria and lung function |
| CN1696281A (en) * | 2004-05-10 | 2005-11-16 | 景岳生物科技股份有限公司 | New microbe gene stock similar to lactobacillus casei GM-O80, and application for treating disease related to irritability |
| CN102008513A (en) * | 2009-09-04 | 2011-04-13 | 蒋盛军 | Method for controlling high swine fever by using nose atomization microecological preparation |
| CN103502434A (en) * | 2011-05-06 | 2014-01-08 | 有机平衡医疗股份公司 | Novel lactic acid bacteria and compositions containing them |
| CN102579687A (en) * | 2012-02-27 | 2012-07-18 | 程相国 | Nasal cavity Chinese medicinal washing fluid |
Non-Patent Citations (2)
| Title |
|---|
| 康白等: "《微生态学现代理论与应用》", 31 January 2013, 上海科学技术出版社 * |
| 易本驰等: "《兽医基础》", 31 August 2007, 中国农业大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018188124A1 (en) * | 2017-04-11 | 2018-10-18 | 成都益植生物科技有限公司 | Colonizing probiotic preparation, applications thereof, and medicament |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104758318B (en) | A kind of compound formulation and preparation method thereof reducing diarrhea of weaned piglets rate | |
| Habryka et al. | Bee products used in apitherapy | |
| CN109464487A (en) | Probiotics compound of anti-helicobacter pylori and preparation method thereof | |
| CN100484964C (en) | New use of tremella heteropolysaccharide or its extract | |
| CN112175864A (en) | Bifidobacterium animalis and breeding method and application thereof | |
| CN108112987A (en) | A kind of functional preparation for adjusting gastrointestinal health and its preparation method and application | |
| Wang et al. | Intestinal microbiota and oral administration of Enterococcus faecium associated with the growth performance of new-born piglets | |
| CN109771470A (en) | A kind of composition and preparation method thereof containing probiotics | |
| JP6596135B2 (en) | Composition for improving intestinal environment, inhibiting weight gain by ingesting a high-fat diet, or inhibiting H. pylori | |
| WO2010077795A2 (en) | Compositions and methods for improved oral health | |
| CN107095292A (en) | It is a kind of that there is plant composite enzyme of regulation gut flora function and preparation method thereof | |
| CN102215849A (en) | Pharmaceutical preparation comprising a combination of streptococcus strains and lactobacillus strains | |
| ES2331650T3 (en) | USE OF PROBIOTIC BACTERIA IN THE TREATMENT OF AN INFECTION. | |
| CN105767543A (en) | Stomach-strengthening and digestion-promoting traditional Chinese medicine micro-ecological preparation for piglet and preparation method thereof | |
| CN103609837A (en) | Lactic acid bacteria powder for suckling pigs as well as preparation method and using method thereof | |
| Soares et al. | Sporeforming probiotic bacteria: Characteristics, health benefits, and technological aspects for their applications in foods and beverages | |
| CN105614000A (en) | Enzyme capable of treating constipation of sows and preparation method of enzyme | |
| CN101926428A (en) | Probiotic gingko pollen freeze-dried powder and preparation method thereof | |
| CN105535580A (en) | A biological agent for improving human body intestinal floras and a preparing method thereof | |
| CN103082294A (en) | Application of bacteroides fragilis in preparation of composition for treating diarrhea | |
| CN114343180A (en) | A series of compositions with effects of clearing hollow viscera and removing toxic substance, and its application | |
| CN104921238A (en) | Toxin-removing and beauty-maintaining health-care beverage and preparation method thereof | |
| CN105362296A (en) | Lactic acid bacteria nasal wash | |
| US20120039860A1 (en) | Compositions and methods for improved oral health | |
| CN104146312B (en) | The health products of regulating gastointestinal function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160302 |